R 172045Z DEC 20
MSGID/GENADMIN/CMC WASHINGTON DC DMCS//
SUBJ/COVID-19 VACCINE GUIDANCE FOR ACTIVE AND RESERVE COMPONENTS//
REF/C/DOC/DHA WASHINGTON DC/13DEC20//
NARR/REF A IS DOD COVID-19 VACCINATION PLAN//
REF B IS MOD 03 to REVISION 01 to DOD RESPONSE TO CORONAVIRUS-2019 EXORD//
REF C IS DEFENSE HEALTH AGENCY INTERIM PROCEDURAL MEMO 20-004, DOD COVID-19 VACCINATION PROGRAM IMPLEMENTATION//
REF D IS NAVADMIN 327/20, SARS-COV-2 VACCINATION AND REPORTING POLICY//
REF E IS DEPSECDEF MEMO, CORONAVIRUS DISEASE 2019 VACCINE GUIDANCE//
REF F IS DODINST 6205.02, DOD IMMUNIZATION PROGRAM//
REF G IS BUMEDINST 6230.15B, IMMUNIZATIONS AND CHEMOPROPHYLAXIS FOR THE PREVENTION OF INFECTIOUS DISEASES//
REF H IS OPNAVINST 3710.7V, NAVAL AIR TRAINING AND OPERATING PROCEDURES STANDARDIZATION GENERAL FLIGHT AND OPERATING INSTRUCTIONS//
REF I IS THE CIVILIAN HEALTH AND MEDICAL PROGRAM OF THE UNIFORMED SERVICES (CHAMPUS)/TRICARE: TRICARE PHARMACY BENEFITS PROGRAM//
POC/OWINGS, ALFRED/CDR/HQMC/HS/DIRECTOR OF PUBLIC HEALTH/TEL: 703-604-4602/EMAIL: ALFRED.OWINGS@USMC.MIL//
POC/CARNEY, LEO/CAPT/HQMC/HS/DIRECTOR OF CLINICAL SERVICES/TEL: 703-604-4602/EMAIL: LEO.CARNEY@USMC.MIL//
POC/MARINE CORPS COVID CELL/HQMC/PP&O/MCCC/TEL: 703-692-4317/EMAIL: SMB_HQMC_MCCAT@USMC.MIL//
POC/MARINE CORPS OPERATIONS CENTER/HQMC/PP&O/MCOC WATCH OFFICER/TEL: 703-695-5454/EMAIL: HQMC.MCC2@USMC.MIL//
POC/PULITANO, MATTHEW/HMC/HQMC/PP&O/MRRS COORDINATOR/TEL: 703-571-1046/EMAIL: MATTHEW.PULITANO@USMC.MIL//
GENTEXT/REMARKS/1. Purpose. Provide guidance to Marine Corps active and reserve components to implement the DOD Coronavirus Disease 2019 (COVID-19) Vaccination Plan in support of Operation Warp Speed (OWS) and the whole-of-government United States (US) response to the global SARS-CoV-2 pandemic. Vaccination of US citizens, to include Department of Defense (DoD) personnel and Military Health System (MHS) beneficiaries, is critical to slowing transmission of SARS-CoV-2 and eventually ending the pandemic in our country. Updated guidance will be published in the form of supplemental MARADMINs as dictated by evolving vaccine availability, evidence, and higher-level directives.
2.a. COVID-19 is a disease caused by infection with the SARS-CoV-2 virus. The spread of SARS-CoV-2 has significantly impacted every aspect of global society, American daily life, and DoD and Marine Corps activities and operations. A SARS-CoV-2 vaccine has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA), and it is expected that one or more additional vaccines will also receive EUA in the coming months. The Marine Corps will support the whole-of-government effort to combat and end the pandemic, preserve Force Health, and enhance Mission Assurance by offering COVID-19 vaccine(s) to its personnel and beneficiaries, in accordance with references (a)-(e) and the following guidance.
2.b. Both the FDA and Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) conduct independent expert reviews before authorizing or recommending use of any COVID-19 vaccine. Initial review of vaccine candidates strongly suggests that these vaccines will be safe, and will be highly effective at preventing symptomatic COVID-19 disease.
3. Authorization, Eligibility, Prioritization, and Distribution.
3.a. Authorization. Eligible Marine Corps personnel and beneficiaries will have the option to receive or decline any COVID-19 vaccine(s) released under EUA. Commanders will ensure that all personnel being offered COVID-19 vaccine(s) are provided required vaccine-specific educational materials, provided the opportunity to ask questions of informed healthcare providers, and provided the opportunity to choose or decline vaccination. While COVID-19 vaccination under EUA will not be mandated, all eligible DoD and Marine Corps personnel and beneficiaries will be offered the COVID-19 vaccine(s), and highly encouraged to be vaccinated after weighing risks and benefits, due to the evidence strongly suggesting that these vaccines will be both safe and effective.
3.b. Eligibility. Marine Corps active and reserve component personnel, civilian employees, and other beneficiaries will be eligible to receive COVID-19 vaccine(s) in accordance with reference (e). Vaccination of eligible persons will occur in priority order, per paragraph 3.c. below. The following are eligible to receive the vaccine(s):
3.b.1. Service members on active duty and in the Selected Reserve.
3.b.2. Dependents, retirees, and other eligible DoD beneficiaries.
3.b.3. DoD civilian employees who are not otherwise eligible DoD beneficiaries.
3.b.4. Select contractor personnel who usually receive influenza vaccines as part of a DoD occupational safety and health program (e.g., healthcare workers, maintenance depot workers).
3.b.5. Select Other Than US Forces (OTUSF) personnel not identified above, as-approved on a case-by-case basis at the DoD level.
3.b.6. Individuals listed in paragraphs 3.b.1 – 3.b.2 are eligible to receive COVID-19 vaccine(s) at Military Treatment Facilities (MTFs) or other approved DoD vaccination sites, or through TRICARE-covered Network providers and pharmacies when-available and approved. Individuals listed in paragraphs
3.b.3, 3.b.4, and if approved, 3.b.5 may only receive COVID-19 vaccines through DoD at MTFs and other approved DoD vaccination sites.
3.c. Prioritization. COVID-19 vaccine will initially be available in limited supply, and will be prioritized for allocation within DoD according to the prioritization schema in Annex C, Appendix 1, of reference (a). Eligible Marine Corps personnel and beneficiaries will be prioritized according to the DoD schema, and Marine Corps-specific prioritization within that schema. In brief, vaccination will be prioritized in the following Phase order:
3.c.1. Phase 1a: Healthcare workers, first responders, and public safety personnel.
3.c.2. Phase 1b.1: Critical national capabilities, Strategic and National mission forces.
3.c.3. Phase 1b.2: Personnel preparing to deploy OCONUS.
3.c.4. Phase 1b.3: Other critical and essential support personnel. The majority of Marine Corps service members will fall into this category.
3.c.5. Phase 2: Beneficiaries at high-risk of severe COVID-19 disease, as defined by the CDC.
3.c.6. Phase 3: Healthy personnel and other beneficiaries.
3.d. Distribution, Allocation, and Ordering.
3.d.1. COVID-19 vaccine distribution in DoD will follow a phased plan, per reference (a). Briefly, COVID-19 vaccine(s) distribution will proceed according to the following Phases:
3.d.1.(a). Phase 1, Pre-Vaccination. Phase entails COVID-19 vaccine planning, and ended with FDA issuance of the first EUA for a COVID-19 vaccine.
3.d.1.(b). Phase 2a, Controlled Pilot/Limited Distribution. Phase begins with promulgation of reference (a) and issuance of FDA EUA of a COVID-19 vaccine. Vaccine will be distributed to twelve CONUS and four OCONUS primary sites, and six secondary sites. Phase ends when the initial sites are allocated vaccine doses and the controlled pilot is validated by DHA per transition criteria in reference (a).
3.d.1.(c). Phase 2b, Expanded Distribution. Phase begins when pilot distribution is validated. Vaccine ordering is transitioned to the Services. Phase ends when 60 percent of total DoD COVID-19 vaccine requirement is met.
3.d.1.(d). Phase 2c, Saturation. Phase begins when 60-plus percent of DoD COVID-19 vaccines have been delivered. Resembles routine vaccination ordering and distribution, with no further need to prioritize orders.
3.d.2. COVID-19 vaccine(s) allocated to DoD will then be allocated to the Services IAW processes outlined in reference (a). Vaccine(s) allocated to DoN will be further allocated to MTFs, and to Navy and Marine Corps commands, per the DoD prioritization schema and reference (d).
3.d.3. HQMC, PP&O, COVID-19 Cell will coordinate with OPNAV COVID-19 Cell to ensure appropriate prioritization and allocation of vaccine within DoN.
3.d.4. Departmental priorities will be provided to the Defense Health Agency (DHA), Navy Bureau of Medicine and Surgery (BUMED), NAVMEDLOGCOM (NMLC), and to MTFs, as-required.
3.d.5. At this time, per reference (d), MTFs will place vaccine orders on behalf of Marine Corps and other supported commands, as well as MTF-assigned beneficiaries.
3.d.6. In the future, as the production and supply of COVID-19 vaccine(s) increases, and less-complex COVID-19 vaccines are released under EUA, individual Commands will likely be given authority to order COVID-19 vaccine(s) directly. Additional detailed ordering guidance will be promulgated at that time.
4.a. At this time, all COVID-19 vaccine(s) administered within DoN will be administered within the MTF or other approved DoD vaccination sites. Due to the complexity of storing, handling, and administering the first vaccine(s) expected to receive EUA, COVID-19 vaccination within DoN will be a centrally-managed process initially. Marine Corps personnel will not handle or administer COVID-19 vaccine at this time, unless under the direction and authority of an MTF or other approved DoD vaccination site.
4.b. When vaccine(s) suitable for storage and transportation at 2 to 8 degrees Celsius receive EUA, and/or when it is determined that one or more of the initial COVID-19 vaccines can be safely transported and administered outside the MTF, updated guidance will be promulgated.
4.c. Per reference (d), MTFs will coordinate the execution and administration of COVID-19 vaccination with local supported commands. Accordingly, Marine Corps Commanders will coordinate with their supporting MTFs, and/or other supporting approved DoD vaccination sites, to ensure their Commands and personnel are accounted for and prioritized appropriately, and to plan and execute vaccination evolutions per MTF or other site direction.
4.d. Due to the potential for side effects that may impact ability to stand duty for 12-72 hours post-vaccination, Commanders will ensure that vaccination events will not impact operational readiness. Specifically, Commanders should consider having critical personnel offered vaccine on a staggered timeline (e.g., 3-5 days apart), to ensure maintenance of operational readiness.
4.e. The majority of candidate COVID-19 vaccines are two-dose series, and are not interchangeable. In addition, COVID-19 vaccines will likely have extremely limited initial availability to DoD. Finally, the effectiveness of two-dose COVID-19 vaccines is estimated based on completion of the series. For these reasons, Commanders will ensure that personnel being offered a first dose of any two-dose COVID-19 vaccine will be available within the vaccine-specific window (21-28 days) to receive the second dose of the same vaccine. Personnel may, however, choose not to receive a second dose, even after receiving the first dose, while the COVID-19 vaccine(s) are authorized under EUA.
4.f. Commanders will ensure that personnel preparing to deploy (Phase 1b.2 in paragraph 3.c) who choose to be vaccinated with a COVID-19 vaccine are scheduled to receive the first dose of any two-dose COVID-19 vaccine series at least 60 days prior to deploying. This will ensure adequate time to receive the second dose and monitor recipients for short-term side effects prior to deploying. Commanders will also ensure that pre-deployment planning accounts for administration of other deployment-related vaccines that may not be recommended for administration on or about the time of COVID-19 vaccine(s) administration.
4.g. Commanders will ensure that all vaccine evolutions incorporate appropriate COVID-19 mitigation measures.
4.h. Commanders will coordinate with supporting MTFs or other approved vaccination sites to ensure that all personnel being offered COVID-19 vaccine(s) under EUA are:
4.h.1. Provided required vaccine-specific educational materials, including the EUA Fact Sheet for Vaccine Recipients;
4.h.2. Counseled by an informed healthcare provider on the risks, benefits, and side effects of the vaccine;
4.h.3. Counseled by an informed provider on alternatives to receiving that vaccine (to include receiving other COVID-19 vaccines when/if authorized);
4.h.4. Provided the opportunity to ask questions of an informed healthcare provider;
4.h.5. Provided the opportunity to choose or decline vaccination;
4.h.6. Medically screened with DHA Form 207, which must be entered into the Electronic Health Record (EHR).
4.i. Commanders will coordinate with supporting MTFs and/or other vaccination sites to ensure the following information is documented in service members’ and civilian personnel’s EHR:
4.i.1. Vaccine information, to include date vaccine was administered, vaccine name or CVX code, manufacturer and lot number, dose administered, route and anatomic site of vaccination, and name of HCP administering the vaccine, OR;
4.i.2. Exemption code “medical, declined” if the individual chooses not to receive the vaccine, OR;
4.i.3. Exemption code “medical, temporary” if the individual cannot receive the vaccine due to a temporary medical contraindication.
4.j. For active duty service members, Commanders will coordinate with MTFs and/or other sites to ensure that the information in 4.i is entered into the Medical Readiness Reporting System (MRRS), in addition to the EHR.
4.k. Personnel who receive COVID-19 vaccination from approved non-DoD facilities (e.g., civilian pharmacies) shall provide documentation, to include all information in 4.i.1, to their command MRRS representative no later than 1600 on the next regular duty day.
4.l. It is expected that MTFs and other approved DoD vaccination sites will enter required information into MRRS. However, if a command needs to enter members’ vaccine information in MRRS (e.g., if vaccinated at a network pharmacy), and the command does not have access, contact the local MRRS security officer or the HQMC MRRS POC listed in this message for further assistance.
4.m. Due to the importance of impact on the pandemic, and limited initial supply of COVID-19 vaccine(s), vaccine documentation is critical. Commanders will coordinate with MTFs, command medical personnel, and command MRRS representatives to ensure that all required documentation occurs in a timely manner, and is thorough and accurate.
4.n. Identification and reporting of vaccine-associated adverse events is equally critical, especially while COVID-19 vaccine(s) remain under EUA, and safety data continues to be collected. Commanders must ensure that any personnel suspected of having an adverse reaction to a COVID-19 vaccine are either evaluated by command medical personnel, or referred to the MTF. Any adverse event must be reported as-specified in 8.a and 8.d below.
5. Command and Control (C2).
5.a. Director, DHA, is tasked with executing reference (a), the DoD COVID-19 Vaccination Plan, per reference (b).
5.b. DoD Components are tasked with supporting Director, DHA, in executing reference (a). HQMC Health Services and PP&O COVID-19 Cell will coordinate responses as-required, to include reporting any Service-specific information required by DHA or higher authority.
5.c. MTFs will support the Services by coordinating the execution and administration of COVID-19 vaccination with local supported commands.
5.d. Commanders are responsible for coordinating with MTFs, or other approved DoD vaccination sites, to ensure that the requirements of this MARADMIN are met, and are responsible for any current or future reporting requirements.
6. Patient Education and Safety.
6.a. Commanders will ensure that all Marine Corps medical staff advising personnel on the risks and benefits of a COVID-19 vaccine review, and are intimately familiar with, this MARADMIN and all vaccine-specific FDA, ACIP, DHA, and manufacturer-specific guidance, including, but not limited to:
6.a.1. Terms of the vaccine-specific FDA EUA.
6.a.2. ACIP recommendations specific to the vaccine.
6.a.3. FDA or manufacturer-specific EUA Fact Sheets for HCPs specific to the vaccine.
6.b. Any Marine Corps personnel or beneficiaries will be provided education, counseling, and an opportunity to choose or decline vaccination as-stated in 4.h.
6.c. Due to the potential for side effects that may impact ability to work for 12-72 hours, Commanders will ensure that vaccination events will not impact operational readiness. Specifically, Commanders may choose to have personnel offered vaccine on a staggered timeline to ensure maintenance of operational readiness.
6.d. Per reference (d), all DoN personnel in a Flight or Dive status will be grounded, or excluded from high-risk activities, for a 72-hour period following mRNA vaccination. At this time, vaccination with any other COVID-19 vaccines will require a 12-hour post-vaccination grounding or high-risk activity avoidance. This guidance will be updated as-required.
6.e. There is no expected need for SARS-CoV-2 testing prior to vaccination with any of the candidate COVID-19 vaccines.
6.f. Previous infection with SARS-CoV-2 is not expected to preclude personnel from receiving a COVID-19 vaccine. However, vaccine administrators (e.g., MTF HCPs) will verify the vaccine-specific guidance regarding previous infection, and medically screen each recipient prior to administering any COVID-19 vaccine(s).
6.g. Initial CDC guidance recommends against administering other vaccines at the same time as, or within a defined time period of, COVID-19 vaccine(s). This guidance may evolve rapidly, and may be different for each COVID-19 vaccine issued under EUA. Vaccine administrators will verify guidance for co-administration for each authorized COVID-19 vaccine prior to administering, and will counsel recipients appropriately. It is recommended that Commanders be continually apprised of current vaccine-specific guidance to ensure proper planning, and to minimize impact on other Force Health Protection measures, including appropriate threat-specific Force vaccination prior to deploying.
6.h. It is expected that COVID-19 vaccines cannot be administered interchangeably to complete a series. Vaccine documentation in MRRS and the EHR is critical to ensure that any indicated second vaccine dose is given with the same product used for the first dose.
7.a. While COVID-19 vaccine handling and administration will initially be managed centrally in the MTFs, it is possible that medical personnel assigned to Marine Corps commands may be called upon to support MTF and other DoD vaccination site evolutions. Any Marine Corps personnel handling or administering COVID-19 vaccine(s) will comply with all training requirements of references (a) – (d), in addition to any site-specific and vaccine-specific training, before handling any COVID-19 vaccine.
7.b. For all Marine Corps personnel handling or administering COVID-19 vaccine(s), mandatory training will include, but is not limited to:
7.b.1. All applicable modules listed in reference (c), Appendix 2, Education and Training Requirements.
7.b.2. Manufacturer’s vaccine-specific online training for all vaccines handled or administered.
8.a. Commanders Critical Information Reports (CCIRs). The following CCIRs are established specifically for Marine Corps COVID-19 vaccine reporting (other COVID-19 CCIRs remain in effect). Changes to CCIRs will be promulgated, as-required, via supplemental MARADMIN. Make reports via OPREP-3 and address all reports to HQMC PP&O, Marine Corps Operations Center as listed in the POC, and operational and administrative chains of command. The MCOC, HQMC PP&O COVID-19 Cell, and/or Health Services will then report to the Joint Staff and courtesy copy DHA Operations (firstname.lastname@example.org), as appropriate.
8.a.1. Adverse reaction to a dose of the vaccine. Report if an individual has a significant adverse or allergic reaction.
8.a.2. COVID-19 infection post-vaccination. Report if a vaccinated individual, regardless of the number of doses, is subsequently diagnosed with COVID-19.
8.a.3. Negative press, social media, or other public interest in the Marine Corps or DoN COVID-19 vaccination process.
8.b. As-directed in paragraphs 4.i – 4.k, document all COVID-19 vaccinations, declinations, and medical exemptions in service members’ EHR and MRRS. HQMC Health Services will consolidate MRRS COVID-19 vaccine data, and communicate that data to the PP&O COVID-19 Cell as-directed. COVID-19 Cell will collate and present data to leadership, and report progress toward saturation.
8.c. MRRS tracking and reporting.
8.c.1. Commanders will ensure that 100% of personnel are offered COVID-19 vaccination.
8.c.2. While under EUA, as-stated in paragraph 4.h, personnel will have the option to decline vaccination, and COVID-19 vaccines will not be considered Readiness vaccines.
8.c.3. Commands will track vaccination in MRRS (and the EHR). MRRS will initially reflect “due” status for all service members. The due status will not, however, impact individual or command Individual Medical Readiness (IMR).
8.c.4. Due status compliance will be achieved by documenting, for each service member: a) administration of a COVID-19 vaccine, b) exempt due to “medical, declined” (declines vaccination), or c) exempt due to “medical, temporary” (unable to receive vaccine due to a temporary medical contraindication). See paragraph 4.i for additional detail.
8.c.5. For tracking and reporting purposes, commands will be considered at-goal for COVID-19 vaccination when 100% of their personnel are documented in MRRS per 8.c.4.
8.c.6. No adverse action may be taken against personnel who decline to receive a vaccine under EUA.
8.d. Adverse Events. Healthcare Providers administering COVID-19 vaccine are required by law to report the below vaccine-associated adverse events to the Vaccine Adverse Event Reporting System (VAERS) at https:(slash)(slash)vaers.hhs.gov/reportevent.html. Because COVID-19 vaccination will be centralized to the MTFs initially, it is expected that MTF HCPs will be largely responsible for VAERS reporting. However, Commanders and unit medical personnel will maintain awareness of personnel post-vaccination, and ensure that any vaccine-associated adverse events are reported by the appropriate entity, and submit a CCIR per paragraph 8.a. The following are required to be reported into VAERS by vaccine administrators if associated with COVID-19 vaccination, per reference (c), Appendix 3:
8.d.1. Vaccine administration errors (whether associated with an adverse event or not).
8.d.2. Multisystem inflammatory syndrome in children (if vaccine is authorized for use in children) or adults.
8.d.3. Cases of COVID-19 that result in hospitalization or death after the recipient has received a COVID-19 vaccine.
8.d.4. Serious adverse events (irrespective of attribution to vaccination), including death, life-threatening events, hospitalization, disability, birth defect, intervention required to prevent permanent impairment, and other serious medical events not specified above.
9.a. Per reference (a), the Marine Corps will develop a COVID-19 vaccine communications strategy and plan. This plan should be consistent with reference (a) Annex F, Public Affairs, and with the DoD COVID-19 Vaccinations Public Affairs Guidance (PAG) dated 8 December 20.
9.b. HQMC Communications Directorate will coordinate development of the communications strategy and plan with other DoN public affairs stakeholders, to include Navy Chief Information Officer (CHINFO) and the BUMED Public Affairs Officer.
9.c. The communications strategy should include, at a minimum, a plan to make Marine Corps personnel and beneficiaries aware of COVID-19 vaccine eligibility, prioritization Phasing, availability, the meaning of EUA, and vaccination impact on individual and Force-wide Force Health Protection posture (see paragraph 10 below).
10. Force Health Protection (FHP) posture. At this time, COVID-19-specific FHP posture will not be altered, individually or Force-wide, regardless of individual vaccination status or command vaccine coverage. It is not currently known whether COVID-19 vaccines being evaluated and issued EUAs prevent asymptomatic carriage and/or transmission of SARS-CoV-2 virus. In addition, while initial vaccine candidates appear to be effective at preventing symptomatic COVID-19 disease, it is not known how long this effect will last, whether booster doses will be required, and if so, how frequently. Finally, it is expected to take 6-12 months before sufficient numbers of US citizens and DoD personnel are vaccinated to approach herd immunity and significantly slow SARS-CoV-2 transmission, and this timeline will depend significantly on the number of personnel who choose to be vaccinated. For those reasons, personnel and commands vaccinated against SARS-CoV-2 will continue to comply with all required COVID-19 FHP requirents, and the Marine Corps will not alter FHP posture and COVID-19 mitigation measures for the foreseeable future.
11. Additional Information and Resources.
11.a. DHA COVID-19 Resource Center, located on the DHA-Immunizations Healthcare Division (DHA-IHD) website at: https:(slash)(slash)www.health.mil/Military-Health-Topics/ Health-Readiness/Immunization-Healthcare/IHD-COVID-19-Vaccine-Resource-Center-for-Health-Care-Personnel.
11.b. DHA-IHD Immunization Healthcare Support Center: 1-877-GET-VACC (1-877-438-8222); or via email at: DoDvaccines@mail.mil. The Support Center can provide clinical consultation, to include assistance with questions regarding vaccine screening and potential vaccine-related adverse events.
11.c. CDC information on COVID-19 vaccination, to include clinical information for each vaccine authorized by the FDA: https:(slash)(slash)www.cdc.gov/vaccines/covid-19/index.html.
11.d. ACIP vaccine-specific recommendations and updates: https:(slash)(slash)www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html.
11.e. MCCC SharePoint: https:(slash)(slash)eis.usmc.mil/sites/hqmcppo/MCCAT/SitePages/Home.aspx.
11.f. MCCC vaccine-specific EUA Fact Sheets and other critical COVID-19 vaccine-related information: https:(slash)(slash)eis.usmc.mil/sites/hqmcppo/MCCAT/Vaccinations.
11.g. Vaccine Adverse Event Reporting System (VAERS): https:(slash)(slash)vaers.hhs.gov/reportevent.html.
12. This MARADMIN is applicable to the Marine Corps total force.
13. This MARADMIN will remain in effect until cancelled or replaced, and will be supplemented as-indicated.
14. Release authorized by Major General Gregg P. Olson, Staff Director of the Marine Corps.//